[EN] SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS [FR] CARBOXAMIDES N-HÉTÉROCYCLIQUES SUBSTITUÉS, SATURÉS ET INSATURÉS ET COMPOSÉS APPARENTÉS POUR LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
[EN] SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS [FR] CARBOXAMIDES N-HÉTÉROCYCLIQUES SUBSTITUÉS, SATURÉS ET INSATURÉS ET COMPOSÉS APPARENTÉS POUR LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
申请人:——
公开号:US20030166654A1
公开(公告)日:2003-09-04
The invention provides compounds of formula (I) wherein n, A, R
1
, R
2
and R
3
are as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as pharmaceuticals.
AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS
申请人:Novartis AG
公开号:EP1282620B1
公开(公告)日:2004-03-31
SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
申请人:Bial - R&D Investments, S.A.
公开号:US20220380314A1
公开(公告)日:2022-12-01
The invention provides substituted, saturated and unsaturated N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.
US6780861B2
申请人:——
公开号:US6780861B2
公开(公告)日:2004-08-24
[EN] AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS<br/>[FR] CARBAMATES AZABICYCLIQUES ET LEUR UTILISATION COMME AGONISTES DES RECEPTEURS NICOTINIQUES ALPHA-7 DE L'ACETYLCHOLINE
申请人:NOVARTIS AG
公开号:WO2001085727A1
公开(公告)日:2001-11-15
The invention provides compounds of formula (I) wherein n, A, R1, R2 and R3 are as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as pharmaceuticals.